Why Is Tyra Biosciences (TYRA) Stock Down -17.15% Today?
Key Takeaways
- TYRA shares plummeted 17.15% to approximately $26.95 in Wednesday trading, following the company's second-quarter earnings release after Tuesday's close.
- Primary catalyst: The company pushed the highly anticipated Phase 2 SURF302 clinical data readout for lead candidate dabogratinib from August to September 2026, rattling investor confidence.
- Secondary drivers: A wider-than-expected Q2 net loss, earnings-per-share miss versus consensus, and the disclosure of an expanded at-the-market (ATM) equity offering capacity of $250 million that raises dilution concerns.
- Broader context: The sell-off occurred against a backdrop of relative strength in the broader biotechnology sector, making TYRA's move company-specific rather than sector-driven.
- What traders are watching: The rescheduled September 2026 SURF302 data release now becomes the make-or-break catalyst for the dabogratinib program and TYRA's near-term trajectory.
Opening Summary
Shares of TYRA, Tyra Biosciences, Inc.—a clinical-stage biotechnology company developing next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology—plunged 17.15% to roughly $26.95 on Wednesday, erasing over $5.50 per share from the prior session's close of $32.53. The steep decline came in reaction to the company's second-quarter 2026 financial results and corporate update released after the market closed on August 4, which revealed a delay in the pivotal Phase 2 SURF302 data readout for dabogratinib, a wider-than-expected quarterly loss, and an expanded at-the-market equity offering capacity.
Clinical Data Delay Shakes Investor Confidence
The central catalyst behind Wednesday's sell-off was the announcement that initial results from the Phase 2 SURF302 study—evaluating oral dabogratinib in patients with FGFR3-altered intermediate-risk non-muscle invasive bladder cancer (IR NMIBC)—would now arrive in September 2026 rather than August, as previously guided. While the company characterized the one-month push as a positive development, noting that patient enrollment had more than doubled from an anticipated 20-plus patients to over 40, the market interpreted the delay as a red flag. For a pre-revenue biotech whose entire investment thesis hinges on near-term clinical catalysts, any shift in the data timeline is typically met with swift punishment. The SURF302 readout is widely regarded as the single most important near-term value driver for TYRA, and uncertainty—even a one-month delay—triggered a wave of selling.
Earnings Miss and Widening Losses Add Pressure
Compounding the disappointment, Tyra Biosciences reported a second-quarter GAAP net loss of $45.6 million, or $0.69 per share, missing the consensus estimate of a $0.64 per share loss. The loss widened sharply from $28.1 million in the same quarter a year ago, driven primarily by higher research and development spending tied to the dabogratinib clinical program. R&D expenses climbed to $39.2 million from $24.3 million in the prior-year period, reflecting expanded activity across the SURF303, SURF302, and BEACH301 trials. With no revenue on the books and an accumulated deficit now exceeding $456 million, the widening cash burn reinforced concerns among investors about the company's runway and capital needs.
ATM Offering Expansion Raises Dilution Fears
Adding another layer of downward pressure, Tyra disclosed that it had amended its at-the-market (ATM) sales agreement with TD Securities, increasing the total offering capacity to $250 million from a previously fully utilized $150 million. The news stoked fears of further shareholder dilution, as the company signaled its willingness to tap equity markets to fund ongoing clinical development. While Tyra ended the quarter with $353.9 million in cash, cash equivalents, and marketable securities—projected to fund operations into the second half of 2028—the expanded ATM facility reminded investors that future capital raises remain likely for a company burning over $40 million per quarter.
Market Context and Trading Activity
The sell-off in TYRA was distinctly company-specific, diverging from the broader biotechnology sector, which has been among the market's strongest-performing groups in 2026. The SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB) have both posted substantial year-to-date gains, buoyed by an improving M&A environment and a friendlier regulatory backdrop. TYRA's decline stood in stark contrast to this favorable sector tailwind, underscoring the stock's sensitivity to pipeline-specific news. Volume surged well above the daily average as investors rushed to reprice the stock following the delayed catalyst and earnings miss. The shares broke decisively below their 50-day moving average, a technical level that had provided support throughout the prior weeks.
Analyst Community Pushes Back Against the Sell-Off
Despite the punishing market reaction, several Wall Street analysts defended the stock. JonesResearch analyst Boris Peaker reiterated a Buy rating with a $56 price target, arguing that the SURF302 data pushout should not be viewed negatively, as the larger patient cohort could provide a more robust dataset to validate dabogratinib's efficacy and safety. H.C. Wainwright's Mitchell Kapoor also maintained a Buy rating and $45 target, expressing confidence that the September readout would demonstrate a three-month complete response rate of at least 70%. Wedbush's Robert Driscoll likewise stood by his Buy rating and $53 target. The gap between analyst conviction and market action highlights the heightened risk tolerance required to hold pre-revenue biotech names through binary clinical catalysts.
What Comes Next for TYRA
The rescheduled September 2026 SURF302 data release now looms as the definitive near-term event for TYRA. Beyond that, the company's "dabogratinib 3x3" strategy positions the drug across three potential blockbuster indications: low-grade upper tract urothelial carcinoma (SURF303, initial results expected in 2027), IR NMIBC (SURF302, September 2026), and achondroplasia (BEACH301, initial safety sentinel cohort results now expected at the end of Q1 2027). The BEACH301 trial has cleared four dose levels without notable safety events and is now enrolling a fifth dose level. Risks remain substantial: the company is entirely dependent on clinical-stage assets, generates no revenue, and faces the binary outcome risk inherent in any Phase 2 oncology readout. Traders and investors will closely watch for any additional updates on enrollment progress and potential early signals ahead of the September data presentation.
Trending AI Robots
For investors seeking data-driven strategies in volatile market environments, Tickeron offers a curated selection of AI-powered trading bots through its Trending AI Robots page. The platform features hundreds of AI trading bots covering thousands of tickers across diverse strategies, timeframes, and performance metrics—yet only the strongest performers under current market conditions are selected for display in this continuously updated section. Each bot operates with a distinct tactical approach, allowing users to explore automated strategies aligned with their individual risk tolerance and investment objectives. Discover which AI trading bots are outperforming right now by visiting the Trending AI Robots page.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TYRA in upward trend: 10-day moving average moved above 50-day moving average on July 10, 2026
The 10-day moving average for TYRA crossed bullishly above the 50-day moving average on July 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on TYRA as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TYRA just turned positive on July 30, 2026. Looking at past instances where TYRA's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .
TYRA moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TYRA advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 208 cases where TYRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where TYRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TYRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TYRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.993) is normal, around the industry mean (20.076). P/E Ratio (0.000) is within average values for comparable stocks, (25.135). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.546). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (412.299).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TYRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement